First Atlas Detailing In Vivo Reflectance Confocal Microscopy Published
ROCHESTER, NY – The In Vivo Reflectance Confocal Microscopy technology helps healthcare practitioners both improve their clinical judgments and assist in monitoring treatment. The first comprehensive atlas detailing the technology is now published.
By: Lucid, Inc
"Reflectance Confocal Microscopy of Cutaneous Tumors: An Atlas with Clinical, Dermoscopic and Histological Correlations"
Specifically, In Vivo Reflectance Confocal Microscopy allows optical sectioning of an area of skin without physical sectioning, assisting dermatologists to examine detailed features of a skin lesion without taking a biopsy specimen. RCM technology can also assist dermatopathologists to determine the best location for a section and dermatological surgeons to determine the margins of a lesion to be excised.
The contents of "Reflectance Confocal Microscopy of Cutaneous Tumors" are:
I. BASIC PRINCIPLES
II. NORMAL SKIN
III. KERATINOCYTIC TUMORS (Seborrheic keratoses, Clear cell acanthoma, Porokeratosis, Squamous neoplasia, Basal cell carcinoma)
IV. MELANOCYTIC TUMORS (Lentigo, Congenital and common acquired melanocytic nevi, Dysplastic nevi, Malignant melanoma, Blue nevus, Spitz nevus)
V. OTHER TUMORS (Trichoepithelioma, Sebaceous hyperplasia, Dermatofibroma, Angioma, Mycosis fungoides)
VI. CLINICAL APPLICATIONS (Adjunct to clinical diagnosis, RCM-guided biopsy site selection, RCM-assisted assessment of treatment response, RCM-assisted in-vivo margin mapping, RCM-Assisted ex-vivo margin assessment)
VII. FUTURE PERSPECTIVES
The editors of the atlas are three of the world’s leading RCM medical researchers:
"Reflectance Confocal Microscopy of Cutaneous Tumors" (ISBN: 9780415451048)
Lucid Inc. an RCM Leader
The leader in the development and worldwide deployment of RCM technology is Lucid, Inc. (www.lucid-tech.com)
Atlas author Dr. González is among several European diagnostic readers providing confocal imaging services for European dermatology patients using Lucid’s VivaScope® Confocal Imagers. The readers are also beginning validation testing of Lucid’s VivaNet® telemedicine information system of transferring and managing clinical data between the private practitioners and the diagnostic readers.
For information on Lucid’s VivaScope® or VivaNet® technology, contact Lucid on the web at http://www.lucid-
Download high resolution photos: www.lucid-
Press contacts: Don Goncalves, 781-793-9380, email@example.com;
# # #
Lucid, Inc., based in Rochester, New York (USA) is a medical device and information company with offices in North America, Europe, and Australia. Lucid is dedicated to providing improved care for dermatology patients by coupling its noninvasive VivaScope® cellular imaging technology with its innovative VivaNet® medical information system to allow secure, HIPAA compliant, near real-time collaboration between dermatologists and other medical specialists. The VivaNet® system provides rapid online medical image transfer, storage, and retrieval thus enabling these critical collaborative consultations. The technologies delivered by Lucid provide images that physicians use in forming critical clinical judgments in cases of dermatologic disease, while ensuring patient comfort and piece of mind.
VivaNet® and VivaScope® are registered trademarks of Lucid, Inc.